<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BA7DE8C2-D98B-4DE6-9EEC-431499D759D2"><gtr:id>BA7DE8C2-D98B-4DE6-9EEC-431499D759D2</gtr:id><gtr:name>National UK Pulmonary Hypertension Centres</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BA7DE8C2-D98B-4DE6-9EEC-431499D759D2"><gtr:id>BA7DE8C2-D98B-4DE6-9EEC-431499D759D2</gtr:id><gtr:name>National UK Pulmonary Hypertension Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/42CDD420-7938-4CD2-A1EE-744440CA0D79"><gtr:id>42CDD420-7938-4CD2-A1EE-744440CA0D79</gtr:id><gtr:firstName>john</gtr:firstName><gtr:surname>wort</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C04DE242-FC3C-4D5A-B576-037A94215D60"><gtr:id>C04DE242-FC3C-4D5A-B576-037A94215D60</gtr:id><gtr:firstName>Ludovic</gtr:firstName><gtr:surname>Vallier</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F1F7D22E-0EA7-491A-A918-B5DCCEC04671"><gtr:id>F1F7D22E-0EA7-491A-A918-B5DCCEC04671</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Gerard</gtr:otherNames><gtr:surname>Coghlan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/75C4A53A-2140-4EB0-996B-0C09BA411106"><gtr:id>75C4A53A-2140-4EB0-996B-0C09BA411106</gtr:id><gtr:firstName>Allan</gtr:firstName><gtr:surname>Lawrie</gtr:surname><gtr:orcidId>0000-0003-4192-9505</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1C99F9DE-08F3-4BA1-930A-3A3F0A994481"><gtr:id>1C99F9DE-08F3-4BA1-930A-3A3F0A994481</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Peacock</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A755A4D8-87BD-4F03-8741-278598939082"><gtr:id>A755A4D8-87BD-4F03-8741-278598939082</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Corris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7EA096EC-1C79-4AA9-8EC3-6FB6858C4309"><gtr:id>7EA096EC-1C79-4AA9-8EC3-6FB6858C4309</gtr:id><gtr:firstName>Stefan</gtr:firstName><gtr:surname>Graf</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/46FA1C3E-B12A-4FD1-B544-89BA1FA09F68"><gtr:id>46FA1C3E-B12A-4FD1-B544-89BA1FA09F68</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Danesh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6D374D11-E09E-4483-9427-B7805F38B2FC"><gtr:id>6D374D11-E09E-4483-9427-B7805F38B2FC</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Glen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AB28FFD0-BF24-463C-A3F1-27E8DF99B613"><gtr:id>AB28FFD0-BF24-463C-A3F1-27E8DF99B613</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Trembath</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DAECA10D-0993-488B-A15B-F062464CA324"><gtr:id>DAECA10D-0993-488B-A15B-F062464CA324</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Wilkins</gtr:surname><gtr:orcidId>0000-0003-3926-1171</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B67F60B5-8FE8-412A-8BDC-6F236F89FC99"><gtr:id>B67F60B5-8FE8-412A-8BDC-6F236F89FC99</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Kiely</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A02E3B12-AD37-43C4-A76C-5B5C1FD42257"><gtr:id>A02E3B12-AD37-43C4-A76C-5B5C1FD42257</gtr:id><gtr:firstName>Willem</gtr:firstName><gtr:surname>Ouwehand</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2FFDB84E-8828-4955-88F5-C99EDB4F8B8E"><gtr:id>2FFDB84E-8828-4955-88F5-C99EDB4F8B8E</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Morrell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK020919%2F1"><gtr:id>5E5BEF8C-4E83-4AD0-A281-DB1ECE338685</gtr:id><gtr:title>Mechanisms underlying the development of pulmonary arterial hypertension</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K020919/1</gtr:grantReference><gtr:abstractText>Severe pulmonary arterial hypertension (PAH) is a rare but devastating condition with greatly reduced life expectancy. The disease is defined as high blood pressure confined to the lungs. Existing treatments improve symptoms for a time but the majority of patients eventually deteriorate and require escalation of therapy or lung transplantation. Many will eventually die from heart failure. We would be better placed to find curative treatments for this condition if we had a deeper understanding of the underlying causes. We have already learned much from genetic discoveries in this disease. Approximately 25% of patients with severe PAH carry defects (mutations) in a gene called BMPR2. The BMPR2 gene codes for a protein that is normally found on the surface of cells that line the inner walls of blood vessels. This protein sends signals to the inside of the cell to prevent it leaking and dying. When BMPR2 is mutated, the cells lining the blood vessels behave abnormally which leads to severe narrowing of the lung arteries. Currently available treatments do not affect this underlying problem and so have little if any effect on the disease process. This project will address major research questions in this field with the aim of providing a greater understanding of disease mechanisms and new clues as to how we can best treat this condition. We now intend to employ the power of modern genetic techniques to find further mutations in patients with PAH in whom we have excluded mutations in BMPR2. Over the last ten years since the discovery of mutations in BMPR2 we have found promising leads in terms of treatment, but these are not straightforward. The prediction is that looking closely for further mutations will provide us with additional targets that might be easier to transform into new treatments. We know that in the families of patients with BMPR2 mutations, there are many individuals with mutations who have not yet developed the disease. This group is at major risk of developing PAH but the environmental factors responsible for triggering the disease remain unknown. We plan to follow up subjects with BMPR2 mutations but who do not yet have the disease over the next 5 years. At 6 monthly follow up subjects will give blood samples, be assessed clinically for signs of disease and will compete a questionnaire designed to detect environmental exposures. This part of the study will provide important information on risk to individuals with certain mutations and provide new information on potential triggers for disease that can then be avoided or used to design new approaches to treatment. As part of this study we will also prepare to capitalise on information learned from the genetic and environmental information. To do this we will generate patient-specific stem cells from a blood test from individuals with BMPR2 mutations (with and without disease) and from patients in whom we find new mutations. We will begin to use these cells to understand how mutations cause changes in important cell types in this disease, including heart and blood vessel cells, and use this as a means of screening new drugs. Finally we will begin to use patient derived samples (stem cells and blood vessel cells) to test our best ideas so far, based on what we have learned from the available genetic information to date. This definitive national study has the potential to provide major new insights into our understanding of the genetic and environmental causes of PAH and has potential to provide promising new approaches to disease prevention or treatment based on these findings.</gtr:abstractText><gtr:technicalSummary>This study seeks to determine novel genetic and environmental factors that contribute to the initiation and/or progression of pulmonary arterial hypertension (PAH). Idiopathic PAH is a rare but devastating condition, predominantly affecting females (2.3:1) in early middle age. The condition continues to carry a poor prognosis (40% mortality at 3 years) despite modern vasodilator therapies. Existing treatment does not target the abnormal vascular cell phenotype that characterises PAH. A major breakthrough in our understanding of the pathobiology was the identification of heterozygous disease-causing mutations in the gene encoding the bone morphogenetic protein type II receptor (BMPR-II) in families with PAH. Although research over the last 10 years has provided important clues, the precise cell and molecular mechanisms leading to disease manifestation remain incompletely understood. In addition, the penetrance of this mutation in families appears low, on average approximately 20%. The existence of discordant monozygotic twins points to important environmental factors. A further 15-26% of apparently sporadic cases of idiopathic PAH harbour mutations in BMPR-II. Identification of the critical environmental and additional genetic factors leading to disease manifestation will lead to strategies for disease prevention and may identify pathways for the development of novel therapies, and provide a basis for reverse translational studies in vitro and in vivo. This study will harness the expertise and unique resources of the UK National Pulmonary Hypertension Centres and allied NIHR BRC next generation sequencing capacity and bioinformatics to identify novel genetic variation underlying PAH. Concurrent epidemiology and biomarker testing will provide clues to environmental triggers. We will derive patient-specific induced pluripotent stem cells to test hypotheses and facilitate target/drug discovery and provide proof-of-concept for targeting the BMPR-II pathway in PAH.</gtr:technicalSummary><gtr:potentialImpactText>This research will provide both academic and, potentially, economic and societal impact. The academic impacts include enhancing the knowledge of the causes, the gene-environment interactions, the natural history, clinical course of heritable forms of pulmonary arterial hypertension (PAH). Although we are studying a rare form of PAH, it is likely to be highly informative, with much broader implications for patients with other forms of pulmonary hypertension, in terms of disease mechanisms and potential therapy. Thus both academics, clinicians and patients are likely to benefit from this research. The findings are likely to inform policy in the management and screening of families where a family member has PAH. An economic and societal impact might be the identification of novel pathways or approaches to treating patients with PAH and the implementation of these through experimental medicine studies. Promising approaches to therapy will be developed by attracting translational funding from research councils or charities, likely in collaboration with industry. 

We anticipate that the use of patient-derived induced pluripotent stem cells (iPSCs) will be a valuable resource for both academia and industry for screening of pathways and compounds in functional assays. These will be made available to the scientific community and industry under the appropriate arrangements for protecting intellectual property. We have already applied for a patent in the UK for our novel method of generating iPSCs from blood outgrowth endothelial cells, using Cambridge Enterprise, the technology transfer arm of the University of Cambridge. With heir help we have non-exclusively licensed the technology to a Cambridge University spin out stem cell company.

As part of this proposal we plan to develop peptidomimetic agents as agonists of the BMPR2 receptor complex. Our preliminary studies with these agents are promising in endothelial cell-based assays. If we can improve the potency of the compounds and confirm their predicted stability in serum we anticipate applying for a patent for these in the near future via Cambridge Enterprise.

The presence of the national cohort will enable studies of prevention and mutation or pathway specific therapies that would otherwise be extremely difficult, given how rare this condition is. This will provide a basis for the identification of novel biomarkers to predict risk of disease in BMPR2 mutation carriers and provide a unique cohort for intervention.

the principal investigator has had previous experience with experimental medicine studies in PAH, taking a drug from proof-of-concept through to a successful international Phase III clinical trial - using the tyrosine kinase inhibitor, imatinib, in patients with advanced PAH.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3193698</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National UK Pulmonary Hypertension Centres</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BHF/MRC National cohort study of heritable pulmonary arterial hypertension</gtr:description><gtr:id>9F35A508-1E94-466D-80D7-E93D29C512FB</gtr:id><gtr:impact>See publications</gtr:impact><gtr:partnerContribution>Research collaboration.</gtr:partnerContribution><gtr:piContribution>National research collaboration to determine the genetic architecture of PAH.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BHF Centres of Regenerative Medicine - iPS Interest Group annual meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FB74FEA2-7C35-4E09-8950-1612C069AC12</gtr:id><gtr:impact>annual meeting

decision making</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Heart Matters - BHF magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9602A6FE-CC8F-4785-9DF3-57C2339DDBB2</gtr:id><gtr:impact>informative article about work carried out at Addenbrooke's hospital, funded by BHF

Public interest</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>200 datafields to describe phenotype of PAH patents recruited to the study.</gtr:description><gtr:id>699B8984-4A53-415A-A718-CBF1061E4A70</gtr:id><gtr:impact>Database will be integrated with whole genome sequencing for genetic studies of phenotypes of PAH.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>OpenClinica PAH database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4F12BFA6-F489-4054-979F-ABA99AF39C81"><gtr:id>4F12BFA6-F489-4054-979F-ABA99AF39C81</gtr:id><gtr:title>Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d937f5f0be2511cd86725eea834e5c4c"><gtr:id>d937f5f0be2511cd86725eea834e5c4c</gtr:id><gtr:otherNames>Toshner M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/414055E6-C80D-49D1-888A-34610AF7813A"><gtr:id>414055E6-C80D-49D1-888A-34610AF7813A</gtr:id><gtr:title>Analysis of Differential Efficacy and Affinity of GABAA (a1/a2) Selective Modulators.</gtr:title><gtr:parentPublicationTitle>Molecular pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19e697164be96f7c746b89d7bc5308d1"><gtr:id>19e697164be96f7c746b89d7bc5308d1</gtr:id><gtr:otherNames>Ain QU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1543-8384</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/676B1372-A548-4083-B379-9347A75E540B"><gtr:id>676B1372-A548-4083-B379-9347A75E540B</gtr:id><gtr:title>Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8e3a6c52710b0b7f914aa4be11c12472"><gtr:id>8e3a6c52710b0b7f914aa4be11c12472</gtr:id><gtr:otherNames>Long L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CE6AAD7-ECF1-496F-BCE6-A8168A7E20A5"><gtr:id>3CE6AAD7-ECF1-496F-BCE6-A8168A7E20A5</gtr:id><gtr:title>BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40d98d0d2b382445c41bf8f9c7fc28dc"><gtr:id>40d98d0d2b382445c41bf8f9c7fc28dc</gtr:id><gtr:otherNames>Evans JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/536BD7B2-6420-4593-9EBD-63C133AAC2C2"><gtr:id>536BD7B2-6420-4593-9EBD-63C133AAC2C2</gtr:id><gtr:title>TNFa drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68abebbad6ec158557ed1eab132c4e9d"><gtr:id>68abebbad6ec158557ed1eab132c4e9d</gtr:id><gtr:otherNames>Hurst LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/572C9E48-F4A4-4F03-9821-746D579DAF88"><gtr:id>572C9E48-F4A4-4F03-9821-746D579DAF88</gtr:id><gtr:title>Regulation of the ALK1 ligands, BMP9 and BMP10.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce73e661495882f5061c864c6e2c1985"><gtr:id>ce73e661495882f5061c864c6e2c1985</gtr:id><gtr:otherNames>Li W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F78A2799-9D44-42EC-9D07-0F533CE5EF76"><gtr:id>F78A2799-9D44-42EC-9D07-0F533CE5EF76</gtr:id><gtr:title>Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8fb3ab981f9170cc7c6f5a14d8bb1e9"><gtr:id>f8fb3ab981f9170cc7c6f5a14d8bb1e9</gtr:id><gtr:otherNames>Rhodes CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1EB54A7-0C9C-4543-A178-EE40C52313B8"><gtr:id>B1EB54A7-0C9C-4543-A178-EE40C52313B8</gtr:id><gtr:title>a1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e18f3a253ab84ca4c59cef0bf6d00a3"><gtr:id>5e18f3a253ab84ca4c59cef0bf6d00a3</gtr:id><gtr:otherNames>Wilkins MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDF4D865-42AC-4DD3-A0C1-730198AD413F"><gtr:id>EDF4D865-42AC-4DD3-A0C1-730198AD413F</gtr:id><gtr:title>Inhibition of Collagenase by Mycosporine-like Amino Acids from Marine Sources.</gtr:title><gtr:parentPublicationTitle>Planta medica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bd7215546df9269323c57b3055da2a03"><gtr:id>bd7215546df9269323c57b3055da2a03</gtr:id><gtr:otherNames>Hartmann A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0032-0943</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C8030A6-1ADE-40C1-BCBE-9FFE47E0FD96"><gtr:id>8C8030A6-1ADE-40C1-BCBE-9FFE47E0FD96</gtr:id><gtr:title>Bone Morphogenetic Protein 9 Enhances Lipopolysaccharide-Induced Leukocyte Recruitment to the Vascular Endothelium.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4ecf03e22310f4e5a0973bfb1e0d4fc"><gtr:id>c4ecf03e22310f4e5a0973bfb1e0d4fc</gtr:id><gtr:otherNames>Appleby SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78704385-B05F-433B-80CB-F6CACABCE018"><gtr:id>78704385-B05F-433B-80CB-F6CACABCE018</gtr:id><gtr:title>Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b3bbe27015d9b0d2dedbe98dbf0e42a"><gtr:id>1b3bbe27015d9b0d2dedbe98dbf0e42a</gtr:id><gtr:otherNames>Ormiston ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/070C20AB-ECD2-4909-8E38-026E4B4F273F"><gtr:id>070C20AB-ECD2-4909-8E38-026E4B4F273F</gtr:id><gtr:title>Cheminformatics Research at the Unilever Centre for Molecular Science Informatics Cambridge.</gtr:title><gtr:parentPublicationTitle>Molecular informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b56c320b57eaae80203e80faebe36c9b"><gtr:id>b56c320b57eaae80203e80faebe36c9b</gtr:id><gtr:otherNames>Fuchs JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1868-1743</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9E9B9C7B-BB2C-4DE2-A62A-73F059F9020E"><gtr:id>9E9B9C7B-BB2C-4DE2-A62A-73F059F9020E</gtr:id><gtr:title>Targeting BMP signalling in cardiovascular disease and anaemia.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0973540d541695707a6b59e7d11d8567"><gtr:id>0973540d541695707a6b59e7d11d8567</gtr:id><gtr:otherNames>Morrell NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-5002</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDAADD32-9C68-435A-BCC2-C556AA884074"><gtr:id>EDAADD32-9C68-435A-BCC2-C556AA884074</gtr:id><gtr:title>Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fb87f2c0325b68566e2326b29236fcb"><gtr:id>5fb87f2c0325b68566e2326b29236fcb</gtr:id><gtr:otherNames>Machado RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D2D7AF8-3499-406E-AB20-23312AFD7F0D"><gtr:id>2D2D7AF8-3499-406E-AB20-23312AFD7F0D</gtr:id><gtr:title>The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Global cardiology science &amp; practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b3bbe27015d9b0d2dedbe98dbf0e42a"><gtr:id>1b3bbe27015d9b0d2dedbe98dbf0e42a</gtr:id><gtr:otherNames>Ormiston ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2305-7823</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/06B60B2D-FECC-486E-AEA2-A46FD4B7F80D"><gtr:id>06B60B2D-FECC-486E-AEA2-A46FD4B7F80D</gtr:id><gtr:title>Pulmonary veno-occlusive disease: characterising a rare but important disease.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/01c5e945aa307d1ad0be78b05f4d2293"><gtr:id>01c5e945aa307d1ad0be78b05f4d2293</gtr:id><gtr:otherNames>Hadinnapola C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CC44B226-07EB-443B-8A9F-F91D3CD8C0E5"><gtr:id>CC44B226-07EB-443B-8A9F-F91D3CD8C0E5</gtr:id><gtr:title>Regulation of bone morphogenetic protein 9 (BMP9) by redox-dependent proteolysis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cbea64da57c26efb70766b9dd060b9c9"><gtr:id>cbea64da57c26efb70766b9dd060b9c9</gtr:id><gtr:otherNames>Wei Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A5BBC51-A5E9-465D-9588-17E45093AE6A"><gtr:id>1A5BBC51-A5E9-465D-9588-17E45093AE6A</gtr:id><gtr:title>Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/afb86e7143e035064ff6be19d8ae6a3a"><gtr:id>afb86e7143e035064ff6be19d8ae6a3a</gtr:id><gtr:otherNames>Soon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB606133-72A4-4856-9FD3-7F186BD1C2C3"><gtr:id>EB606133-72A4-4856-9FD3-7F186BD1C2C3</gtr:id><gtr:title>Circulating Bmp10 acts through endothelial Alk1 to mediate flow-dependent arterial quiescence.</gtr:title><gtr:parentPublicationTitle>Development (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/488f19b8edf62bfa8697bb6af71937f2"><gtr:id>488f19b8edf62bfa8697bb6af71937f2</gtr:id><gtr:otherNames>Laux DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-1991</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2C8C0D3-11E5-4520-955E-741265339D7A"><gtr:id>F2C8C0D3-11E5-4520-955E-741265339D7A</gtr:id><gtr:title>Connexin-mediated regulation of the pulmonary vasculature.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/95e9c2e463e22500a4e7c0b5606e5faa"><gtr:id>95e9c2e463e22500a4e7c0b5606e5faa</gtr:id><gtr:otherNames>Dempsie Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B4C3CD3-2073-47EB-BD87-0BC9FA0C6F16"><gtr:id>4B4C3CD3-2073-47EB-BD87-0BC9FA0C6F16</gtr:id><gtr:title>Intrinsic flexibility of NLRP pyrin domains is a key factor in their conformational dynamics, fold stability, and dimerization.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/178e16c3233e192e665a6bb8b365c01c"><gtr:id>178e16c3233e192e665a6bb8b365c01c</gtr:id><gtr:otherNames>Huber RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31A7F0BD-281A-4424-B01F-3242D7BACB45"><gtr:id>31A7F0BD-281A-4424-B01F-3242D7BACB45</gtr:id><gtr:title>Towards a molecular classification of pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b1d5caf25a6fe1ce64cb58f59efe7903"><gtr:id>b1d5caf25a6fe1ce64cb58f59efe7903</gtr:id><gtr:otherNames>Gr?f S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K020919/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>